Overview

Examination of Pirfenidone (Esbriet®) Therapy in Coal Workers' Pneumoconiosis With Pulmonary Fibrosis

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Examination of pirfenidone (Esbriet®) therapy in coal workers' pneumoconiosis (black lung) with pulmonary fibrosis (scarring of the lung).
Phase:
Phase 2
Details
Lead Sponsor:
Pulmonary Research of Abingdon, LLC
Collaborator:
Genentech, Inc.
Treatments:
Pirfenidone